Overview Dividends

(CRMD) CorMedix - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US21900C3088

Antimicrobial, Catheter, Solution, Infection, Prevention

Pharmaceuticals
Market Cap in USD: 976m
IPO / Inception: 2010-03-25
Return 12m vs S&P 500: 23.5%

EPS (Earnings per Share)

EPS (Earnings per Share) of CRMD over the last years for every Quarter: "2020-12": -0.19, "2021-03": -0.2, "2021-06": -0.12, "2021-09": -0.22, "2021-12": -0.2, "2022-03": -0.18, "2022-06": -0.19, "2022-09": -0.17, "2022-12": -0.2, "2023-03": -0.24, "2023-06": -0.25, "2023-09": -0.17, "2023-12": -0.26, "2024-03": -0.25, "2024-06": -0.25, "2024-09": -0.05, "2024-12": 0.22, "2025-03": 0.2993, "2025-06": 0.28, "2025-09": 1.406,
EPS CAGR: 123.33%
EPS Trend: 68.3%
Last SUE: 4.00
Qual. Beats: 5

Revenue

Revenue of CRMD over the last years for every Quarter: 2020-12: 0.055713, 2021-03: 0.088261, 2021-06: 0.008191, 2021-09: 0.038088, 2021-12: 0.056397, 2022-03: 0.007636, 2022-06: 0.021253, 2022-09: 0.006817, 2022-12: 0.029702, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.30411, 2024-03: 0, 2024-06: 0.806119, 2024-09: 11.456115, 2024-12: 31.209936, 2025-03: 39.081657, 2025-06: 39.73679, 2025-09: 104.275289,
Rev. CAGR: 643.33%
Rev. Trend: 84.5%
Last SUE: 4.00
Qual. Beats: 5

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 78.1%
Value at Risk 5%th 98.2%
Relative Tail Risk -23.58%
Reward TTM
Sharpe Ratio 0.81
Alpha 29.54
CAGR/Max DD 0.81
Character TTM
Hurst Exponent 0.443
Beta 0.609
Beta Downside 0.208
Drawdowns 3y
Max DD 56.88%
Mean DD 24.46%
Median DD 26.77%

Description: CRMD CorMedix November 18, 2025

CorMedix Inc. (NASDAQ: CRMD) is a U.S.–based biopharmaceutical firm that develops and commercializes therapeutics for life-threatening conditions, with its flagship candidate, DefenCath, a catheter-lock solution designed to lower catheter-related bloodstream infections in adult dialysis patients.

Founded in 2006 and headquartered in Berkeley Heights, New Jersey, the company rebranded from Picton Holding Company to CorMedix in January 2007. It trades as a common stock under the GICS sub-industry “Pharmaceuticals.”

Key market context: the global catheter-related infection market is estimated at > $1 billion annually, driven by an aging population and rising prevalence of end-stage renal disease (≈ 750,000 U.S. patients on dialysis). As of the latest quarterly filing (Q2 2024), CorMedix reported a cash runway of roughly $15 million and a quarterly burn of about $2 million, giving it ~ 7-8 months of operating liquidity absent additional financing.

Sector drivers include heightened hospital focus on infection control and potential reimbursement pathways under Medicare’s bundled payment models, which could improve the commercial viability of antimicrobial lock solutions if clinical data demonstrate cost-savings.

For a deeper quantitative assessment, you may want to explore ValueRay’s detailed financial model for CRMD.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (162.5m TTM) > 0 and > 6% of Revenue (6% = 12.9m TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA 82.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 58.74% (prev 435.1%; Δ -376.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.10 (>3.0%) and CFO 75.0m <= Net Income 162.5m (YES >=105%, WARN >=100%)
Net Debt (100.4m) to EBITDA (112.3m) ratio: 0.89 <= 3.0 (WARN <= 3.5)
Current Ratio 1.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (86.2m) change vs 12m ago 46.56% (target <= -2.0% for YES)
Gross Margin 92.61% (prev 83.54%; Δ 9.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 51.74% (prev 16.20%; Δ 35.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 110.8 (EBITDA TTM 112.3m / Interest Expense TTM 974.9k) >= 6 (WARN >= 3)

Altman Z'' 1.49

(A) 0.17 = (Total Current Assets 259.5m - Total Current Liabilities 133.6m) / Total Assets 750.9m
(B) -0.25 = Retained Earnings (Balance) -190.6m / Total Assets 750.9m
(C) 0.26 = EBIT TTM 108.0m / Avg Total Assets 414.2m
(D) -0.51 = Book Value of Equity -190.4m / Total Liabilities 376.7m
Total Rating: 1.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 92.06

1. Piotroski 7.0pt
2. FCF Yield 6.96%
3. FCF Margin 34.73%
4. Debt/Equity 0.40
5. Debt/Ebitda 0.89
6. ROIC - WACC (= 12.07)%
7. RoE 81.83%
8. Rev. Trend 84.54%
9. EPS Trend 68.29%

What is the price of CRMD shares?

As of December 26, 2025, the stock is trading at USD 12.19 with a total of 957,669 shares traded.
Over the past week, the price has changed by +2.27%, over one month by +29.68%, over three months by +9.62% and over the past year by +43.41%.

Is CRMD a buy, sell or hold?

CorMedix has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CRMD.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CRMD price?

Issuer Target Up/Down from current
Wallstreet Target Price 19 55.9%
Analysts Target Price 19 55.9%
ValueRay Target Price 13.9 14.1%

CRMD Fundamental Data Overview December 24, 2025

Market Cap USD = 976.2m (976.2m USD * 1.0 USD.USD)
P/E Trailing = 5.6063
P/E Forward = 4.4723
P/S = 4.5552
P/B = 2.6092
Beta = 1.325
Revenue TTM = 214.3m USD
EBIT TTM = 108.0m USD
EBITDA TTM = 112.3m USD
Long Term Debt = 144.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.42m USD (from shortTermDebt, last quarter)
Debt = 148.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 100.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (976.2m + Debt 148.9m - CCE 55.7m)
Interest Coverage Ratio = 110.8 (Ebit TTM 108.0m / Interest Expense TTM 974.9k)
FCF Yield = 6.96% (FCF TTM 74.4m / Enterprise Value 1.07b)
FCF Margin = 34.73% (FCF TTM 74.4m / Revenue TTM 214.3m)
Net Margin = 75.83% (Net Income TTM 162.5m / Revenue TTM 214.3m)
Gross Margin = 92.61% ((Revenue TTM 214.3m - Cost of Revenue TTM 15.8m) / Revenue TTM)
Gross Margin QoQ = 89.26% (prev 95.31%)
Tobins Q-Ratio = 1.42 (Enterprise Value 1.07b / Total Assets 750.9m)
Interest Expense / Debt = 0.64% (Interest Expense 948.2k / Debt 148.9m)
Taxrate = -106.5% (out of range, set to none) (-56.0m / 52.6m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.94 (Total Current Assets 259.5m / Total Current Liabilities 133.6m)
Debt / Equity = 0.40 (Debt 148.9m / totalStockholderEquity, last quarter 374.1m)
Debt / EBITDA = 0.89 (Net Debt 100.4m / EBITDA 112.3m)
Debt / FCF = 1.35 (Net Debt 100.4m / FCF TTM 74.4m)
Total Stockholder Equity = 198.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.64% (Net Income 162.5m / Total Assets 750.9m)
RoE = 81.83% (Net Income TTM 162.5m / Total Stockholder Equity 198.6m)
RoCE = 31.48% (EBIT 108.0m / Capital Employed (Equity 198.6m + L.T.Debt 144.5m))
RoIC = 19.24% (EBIT 108.0m / (Assets 750.9m - Curr.Liab 133.6m - Cash 55.7m))
WACC = 7.17% (E(976.2m)/V(1.13b) * Re(8.26%) + (debt cost/tax rate unavailable))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.56%
[DCF Debug] Terminal Value 80.74% ; FCFE base≈74.4m ; Y1≈91.8m ; Y5≈156.6m
Fair Price DCF = 32.42 (DCF Value 2.55b / Shares Outstanding 78.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 68.29 | EPS CAGR: 123.3% | SUE: 4.0 | # QB: 5
Revenue Correlation: 84.54 | Revenue CAGR: 643.3% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.72 | Chg30d=+0.200 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=2.50 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-5.1% | Growth Revenue=+40.8%

Additional Sources for CRMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle